FGL

FGL is a synthetic 15-amino-acid peptide that mimics the FG loop region of the second fibronectin type III (F3) module of the neural cell adhesion molecule (NCAM). NCAM is a transmembrane glycoprotein involved in cell-cell adhesion, axon outgrowth, synaptic plasticity, and learning. The FG loop region mediates NCAM's interaction with fibroblast growth factor receptor 1 (FGFR1). FGL reproduces this interaction and activates FGFR1 directly, bypassing the need for full NCAM engagement.

The compound was developed in the lab of Elisabeth Bock and Vladimir Berezin at the University of Copenhagen as part of a broader program to develop peptide mimetics of cell adhesion molecules. The strategy targets the protein-protein interaction interfaces that mediate NCAM signaling and produces compact peptide agonists that retain the biological activity of the much larger parent molecule.

The development rationale ties to a substantial body of work establishing NCAM's role in synaptic plasticity and learning:

• NCAM-deficient mice show impairments in learning, memory, and synaptic plasticity
• NCAM polysialylation is dynamically regulated during learning processes
• NCAM-FGFR1 signaling is essential for several forms of synaptic plasticity
• Pharmacological enhancement of NCAM-FGFR1 signaling has emerged as a target for cognitive enhancement and treatment of neurodegenerative disease

The Animal Evidence

Published work has tested FGL in multiple cognitive paradigms:

Klementiev et al., 2007. Aged rats treated with FGL showed improvement in spatial learning and memory in the Morris water maze test. The aged-rat model is relevant for age-related cognitive decline and provides a translatable framework for evaluating compounds intended for human cognitive aging applications.

Aonurm-Helm et al., 2008. FGL rescued behavioral deficits in NCAM-deficient mice, supporting the proposed mechanism of NCAM-FGFR1 pathway activation.

Secher et al., 2006. Pharmacological characterization of FGL including effects on FGFR1 binding, downstream signaling, and neurite outgrowth in cell culture.

Mechanism work has extended to characterization of FGL effects on long-term potentiation (LTP, a cellular model of synaptic plasticity associated with learning), neurotrophic factor expression, and neuroprotection in stress models.

The animal dataset is concentrated within the Bock-Berezin research program and collaborators. Independent replication by groups outside this network has been limited.

The Human Evidence

There is none.

No registered ClinicalTrials.gov trial exists for FGL. No Phase 1 safety data has been published. The compound has not progressed to human dose-finding or proof-of-concept testing as of May 2026.

The development trajectory from rodent cognitive enhancement to human clinical efficacy has historically been difficult. Many promising preclinical cognitive enhancers have failed in human trials due to a combination of pharmacokinetic limitations, effect size differences between rodent models and human populations, and trial design challenges. Whether FGL would translate the rodent findings to human cognitive aging applications is unknown.

Regulatory and Legal Status

FDA. No approval. No IND filing visible in public records.

EMA. No approval.

Compounding. Not on FDA bulk drug substances list.

WADA. Not on 2026 Prohibited List.

Research-chemical availability. Some vendors offer FGL-labeled product. Identity verification is the buyer's responsibility.

The mechanism is direct FGFR1 activation through mimicry of the NCAM FG loop interaction site.

NCAM biology. NCAM is a transmembrane glycoprotein with three immunoglobulin-like domains and two fibronectin type III (F3) modules in its extracellular region. The second F3 module contains the FG loop, which mediates NCAM's interaction with FGFR1. When NCAM engages FGFR1, it triggers receptor dimerization, autophosphorylation, and downstream signaling through MAPK/ERK, PI3K/Akt, and PLC-gamma pathways.

FGL design. The synthetic peptide reproduces the 15-amino-acid FG loop sequence. The compact size enables direct FGFR1 engagement without the rest of the NCAM molecule. The peptide acts as a partial agonist at FGFR1, triggering downstream signaling at concentrations relevant for cognitive applications.

Downstream consequences. FGFR1 activation supports:

• Neurite outgrowth in developing and adult neurons
• Long-term potentiation in hippocampal synaptic plasticity
• Neurotrophic factor expression (BDNF, NGF, others)
• Neuroprotection against various stressors
• Modulation of adult hippocampal neurogenesis

These downstream effects are mechanistically linked to the cognitive enhancement observed in aged-rat behavioral studies.

Pharmacokinetics. Specific human PK data is not available. Rodent studies have used intranasal, subcutaneous, and intracerebroventricular routes. The intranasal route is particularly attractive for CNS-active peptides because of direct nose-to-brain transport via olfactory and trigeminal nerve pathways. FGL's 15-amino-acid size is manageable for intranasal delivery.

Off-target activity. FGFR1 is expressed in tissues outside CNS. Chronic systemic FGFR1 activation has theoretical implications for tissue homeostasis, growth, and possibly carcinogenesis. These concerns apply more strongly to chronic high-dose systemic administration than to short-course intranasal use.

Human pharmacokinetic data is not published.

Animal-model effects from published preclinical work:

• Improvement in spatial learning and memory in aged rats
• Rescue of behavioral deficits in NCAM-deficient mice
• Enhancement of long-term potentiation in hippocampal slice preparations
• Neuroprotective effects in stress and toxicity models
• Possible effects on adult hippocampal neurogenesis

Research-chemical user reports outside investigational settings describe:

• Subjective improvement in memory, particularly working and spatial memory
• Enhanced focus and verbal fluency
• Subtle mood-elevating effects in some users
• Possible synergistic effects when combined with other nootropic peptides

User reports are anecdotal, uncontrolled, and not verified for vial identity. The reported subjective benefits are particularly susceptible to placebo effects and expectation bias.

No standardized human dosing protocol exists for FGL because no human clinical trial has been published.

Rodent studies have used a variety of dosing routes and concentrations. Intranasal and subcutaneous administration have been most common in cognitive-enhancement protocols.

Research-chemical user protocols typically use:

• Intranasal administration at 200 to 500 mcg per day
• Subcutaneous administration at similar daily totals
• Cycle lengths of 4 to 8 weeks with breaks between cycles

These doses are extrapolated from rodent body-surface-area scaling and informal community experience. They are not supported by clinical pharmacokinetic data.

Animal toxicology has not flagged dose-limiting toxicity in the rodent studies published to date. Long-term human safety data does not exist because the compound has not entered human clinical testing.

Theoretical concerns based on mechanism and class:

• FGFR1 activation in peripheral tissues at chronic high doses could affect tissue homeostasis and growth
• Theoretical implications for carcinogenesis with sustained FGFR1 agonism are not fully characterized
• Effects on adult neurogenesis with chronic high-dose use could affect neural circuit homeostasis
• Drug-drug interactions with FGFR inhibitor cancer therapies, antidepressants, and other CNS-active medications have not been studied

These concerns are mechanistic flags that Phase 1 safety studies would normally address. Those studies have not occurred.

FGL is in the broader category of peptide growth factor mimetics for cognitive applications. The closest mechanistic peers are:

• Dihexa — Hepatocyte growth factor (HGF) mimetic angiotensin IV analog with synaptogenesis claims through a different receptor pathway
• P-21 — CNTF mimetic with neurogenesis and tau-pathology effects in AD models
• Cerebrolysin — Peptide mixture with broad neurotrophic effects, established clinical use in some European countries

For nootropic stacking, FGL is sometimes combined with Selank, Semax, or Noopept for broader cognitive coverage. None of these combinations has been studied in controlled human trials.

External comparators in the cognitive-enhancement therapeutic landscape are limited. For age-related cognitive decline without diagnosed dementia, no FDA-approved pharmacotherapy exists; lifestyle interventions (exercise, social engagement, cognitive training, sleep optimization) have the strongest evidence base. For Alzheimer's disease specifically, cholinesterase inhibitors and memantine address symptoms, and the amyloid-targeting antibodies (lecanemab, donanemab) address pathology in early disease.

FGL has no comparable evidence base and is not a substitute for any of these established approaches in clinically significant cognitive disease. Its appeal is primarily mechanistic: a defined peptide acting on a well-characterized receptor pathway involved in synaptic plasticity. The translation from rodent enhancement to human application remains unproven.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.